Safety, immunogenicity, and anti-HBV activity, presented in chronically HBV-infected patients following a single, prime-only, or a prime and boost, intramuscular injection of VRON-0200 Over 7,680 ...

Ocean Biomedical, Inc. (NASDAQ: OCEA) announces that its joint venture partner, Virion Therapeutics, has dosed its first patient in the Phase 1b clinical trial of its investigational VRON-0200 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Virion was recently awarded a ...

PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and Ocean Biomedical, Inc. (NASDAQ: OCEA), a ...

.Over 8,295 and 821 safety days reported in VRON-0200 alone (n=27), and VRON-0200 combination treated patients (n=7), respectively; VRON-0200 was well tolerated, with no serious treatment-related ...

Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026 Virion ...

LONDON--(BUSINESS WIRE)--Virion Biotherapeutics announced today the appointments of Vanessa King, PhD, as President & Chief Executive Officer and Isabel Najera, PhD, as Chief Scientific Officer.

(MENAFN- EIN Presswire) This“Spark and Fan” treatment strategy could potentially offer a simple and well tolerated solution for a wide range of future HBV functional cure regimens for patients ...

Wistar Institute spinout company Virion Therapeutics raised a $4 million angel round, according to an SEC filing. The immunotherapy company is working on a path to commercialization for a set of ...

Providence, Rhode Island, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research ...